Vitasoy International Holdings Limited reported unaudited consolidated earnings results for the year ended March 31, 2017. For the year, the company's revenue was HKD 5,406,090,000 compared to HKD 5,551,898,000 a year ago. Profit from operations was HKD 848,034,000 against HKD 603,352,000 a year ago. Profit before taxation was HKD 843,677,000 against HKD 599,308,000 a year ago. Profit attributable to equity shareholders of the company was HKD 618,372,000 or 58.4 cents per diluted share against HKD 530,616,000 or 50.4 cents per diluted share a year ago. The Group's revenue decreased by 3% compared to last year, due to the divestiture of the North American Mainstream and SAN SUI Business (North American divestiture). Excluding the impact of the North American divestiture, the Group achieved a revenue increase of 6% against last year in Hong Kong dollars, equivalent to an increment of 8% on a constant currency basis. EBITDA for the year was HKD 1,083 million, up 33% year-on-year. Excluding the North American divestiture, EBITDA increased by 6%, mainly driven by higher gross profit and cost savings. Profit from operations increased by 41% compared to last year. Excluding the impact of the North American divestiture, profit from operations increased by 3% compared to the previous year. Profit before taxation improved by 41% compared to last year. Excluding the impact of the North American divestiture, profit before taxation improved by 3% - mainly due to a reduction in net finance costs as a result of prudent cash flow management, in spite of a moderate increase in depreciation and amortisation charges. Profit attributable to equity shareholders of the company increased 16% compared to the previous year. Excluding the impact of the North American divestiture, profit attributable to equity shareholders of the company increased by 2%, mainly due to improvements in operating profit and reduction in net finance costs, and partly offset by higher tax charges. Capital expenditure incurred during the year decreased to HKD 197 million compared to HKD 714 million a year ago. The significant drop was because the Wuhan plant construction was completed and production lines were added in Foshan plant. The capital expenditure was invested in the construction of new plant in Wuhan, Mainland China, as well as upgrade of existing production machinery in both Hong Kong and Mainland China.